Mangalam Drugs & Organics Limited (NSE:MANGALAM)
India · Delayed Price · Currency is INR 69.50
-0.69 (-0.98%)
Oct 20, 2025, 3:29 PM IST
Mangalam Drugs & Organics Revenue
Mangalam Drugs & Organics had revenue of 572.09 million INR in the quarter ending June 30, 2025, a decrease of -25.21%. This brings the company's revenue in the last twelve months to 2.98 billion, down -16.41% year-over-year. In the fiscal year ending March 31, 2025, Mangalam Drugs & Organics had annual revenue of 3.18 billion, down -13.55%.
Revenue (ttm)
2.98B
Revenue Growth
-16.41%
P/S Ratio
0.37
Revenue / Employee
6.21M
Employees
480
Market Cap
1.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.18B | -497.78M | -13.55% |
| Mar 31, 2024 | 3.67B | -28.42M | -0.77% |
| Mar 31, 2023 | 3.70B | -806.66M | -17.89% |
| Mar 31, 2022 | 4.51B | 708.84M | 18.65% |
| Mar 31, 2021 | 3.80B | 976.24M | 34.57% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 274.80B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |